Arthneeti

Dishman Carbogen Amcis Q1 FY27 Share Price & Earnings Call Analysis

₹149.42+0.38% today
Market cap
₹2,335 Cr
P/E
128.70
ROE
1.58%
PEG
0.94
Price to sales
0.80
Debt to equity
0.46
52W high / low
₹298 / ₹130
Sales growth (5Y)
8.93%
EBITDA margin
16.72%
Net profit margin
3.37%
Promoter holding
59.32%
Sales (last year)
₹2,901 Cr

Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants with presence in Switzerland, UK, Europe, China and other countries.[1]

Guidance scorecard · Q1 FY27 call

What Dishman Carbogen Amcis Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology

#76of 83 in
Pharmaceuticals & Biotechnology
Revenue10–20%MarginsFlatCapexPlannedFundraisingPlannedOrder bookWhat management said

RevenueQ1 FY27 call

10–20%
  • FY27 revenue expected to grow by at least 30-35% for the Indian entity.
  • Overall company expects single-digit revenue growth for FY27 due to deferral of some orders and market conditions.
  • FY28-29 outlook anticipates substantial growth across India operations, Swiss CDMO, and French injectables plant.
  • Expectation of more than 10% year-on-year revenue growth in FY28-29.
  • Double-digit growth forecasted for French and Indian entities during FY28-29.
  • New tech transfers from Switzerland to India and advanced discussions on more transfers support growth.

2 more points from Dishman Carbogen Amcis Ltd's call on revenue

Create a free account to keep reading this call

Full Q1 FY27 analysis

MarginsQ1 FY27 call

Flat

See what Dishman Carbogen Amcis Ltd said on margins — free account, 30 seconds.

Full Q1 FY27 analysis

CapexQ1 FY27 call

Planned
  • Ongoing co-investment with a Japanese customer: The second co-investment is expected to be completed during the next calendar year, adding capacity to provide more quantities to the customer.
  • External Commercial Borrowing (ECB): Approved by RBI to raise funds at promoter entity level, which will be infused in the Indian entity primarily to prepay high-cost debt and finance future CapEx and working capital requirements.
  • CapEx of CHF 4.9 million incurred in Q1 FY27.

2 more points from Dishman Carbogen Amcis Ltd's call on capex

Create a free account to keep reading this call

Full Q1 FY27 analysis

FundraisingQ1 FY27 call

Planned

See what Dishman Carbogen Amcis Ltd said on fundraising — free account, 30 seconds.

Full Q1 FY27 analysis

Order bookQ1 FY27 call

  • Order income is picking up, though market pressure continues.
  • Several big pharma audits resulted in positive outcomes, leading to acquisition of new projects.
  • Over 13 late phase projects, including PPQ campaigns, in portfolio with multiple Phase II projects successfully transformed into late phase programs.
  • More RFPs (Requests for Proposals) are being received, indicating increased interest, but revenue translation may extend into next financial year.
  • Co-investment with Japanese clients progressing, expected completion next calendar year to provide additional capacity.
  • A recent commercial product approval indicates potential for increasing order volumes.

2 more points from Dishman Carbogen Amcis Ltd's call on the order book

Create a free account to keep reading this call

Full Q1 FY27 analysis
Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Dishman Carbogen Amcis Ltd rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹556 Cr22.1
240%+Up 0–2%₹215 Cr22.2
340%+Flat₹16,144 Cr—
440%+Flat₹6,072 Cr48.0
540%+Flat₹40 Cr—
620–40%Up 2%+₹50,220 Cr43.8

Sign up free to see every company in the sector ranking and track Dishman Carbogen Amcis Ltd.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Dishman Carbogen Amcis Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Dishman Carbogen Amcis Ltd

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +619723587651655524789682716708653720851
Expenses +567602526610592495642542564567504607688
Operating Profit5112261416329147140153141149113163
OPM %8%17%10%6%10%6%19%21%21%20%23%16%19%
Other Income +-397564-448-4228715
Interest24282733313237494243424643
Depreciation76707580857172727981848489
Profit before tax-8829-36-66-49-784227283931-1046
Tax %-19%42%13%-10%42%0%21%83%-56%39%-114%24%53%
Net Profit +-7117-41-60-70-78335432365-1322
EPS in Rs-4.511.08-2.61-3.80-4.46-4.952.110.302.751.494.16-0.831.39

Financials of Dishman Carbogen Amcis Ltd

Profit & Loss

Annual income statement trend

Mar 2011Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +1,0311,7141,6952,0592,0441,9122,1412,4132,6162,7122,932
Expenses +8301,2611,2491,5071,5401,6381,8092,0812,3292,2432,366
Operating Profit201452445552503274331332286469566
OPM %20%26%26%27%25%14%15%14%11%17%19%
Other Income +14264654391629-2022452
Interest5649495762485786120159174
Depreciation69214211240283308308281311294339
Profit before tax91216231309197-65-4-55-12219105
Tax %12%33%33%32%20%154%-524%-45%26%83%7%
Net Profit +80145155210159-16518-30-153397
EPS in Rs9.5813.0310.10-10.531.15-1.90-9.790.216.22
Dividend Payout %0%0%0%2%0%0%0%0%0%0%0%

Financials of Dishman Carbogen Amcis Ltd

Balance Sheet

Capital structure and asset base

Mar 2011Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital160.00323231313131313131
Reserves8634,8145,0755,3475,6845,6675,5185,7785,5965,8006,646
Borrowings +8689501,0951,0421,3571,5891,8302,2092,3132,3893,076
Other Liabilities +3348119678991,1211,0681,2551,4211,6311,7662,170
Total Liabilities2,0816,5747,1697,3218,1938,3568,6349,4399,5719,98711,923
Fixed Assets +1,0124,8525,0665,0985,6785,6985,7736,1886,7247,0558,371
CWIP3071331511752344867801,043646467275
Investments1401961671911723242491029791
Other Assets +7611,5501,7571,8812,0912,0001,7581,9592,0982,3683,186
Total Assets2,0816,5747,1697,3218,1938,3568,6349,4399,5719,98711,923

Financials of Dishman Carbogen Amcis Ltd

Cash Flows

Operating, investing and financing cash movement

Mar 2011Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +203303226282585513355266379375491
Cash from Investing Activity +-231-107-297-169-442-380-619-494-225-196-245
Cash from Financing Activity +25-13778-102-98-11130250-22-102201
Net Cash Flow-35971146122-1332213277447
Free Cash Flow-3716422-26177147-101-35276160225
CFO/OP107%92%58%75%131%206%124%90%139%86%88%

Financials of Dishman Carbogen Amcis Ltd

Ratios

Working capital efficiency and return ratios

Mar 2011Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days60619679103808189689084
Inventory Days272473525496462402526568540655910
Days Payable17295201176226132158155149168189
Cash Conversion Cycle160439419399340350449502458577805
Working Capital Days-52354443-10-2-8-37-148-35-58
ROCE %5%6%4%0%1%1%0%2%3%

Guidance history

How Dishman Carbogen Amcis Ltd's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q1 FY27 call →10–20%FlatPlannedPlanned—
Q4 FY26 call →10–20%FlatNone plannedPlannedRising
Q3 FY26 call →10–20%Up 2%+PlannedPlannedRising
Q2 FY26 call →10–20%Up 2%+PlannedPlannedRising

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

7out of 100

Momentum score · price trend

7 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months−49.0%5%
Last 6 months−18.4%21%
Last 3 months−19.4%18%

The price is 61% below its all-time high of ₹383 (25 Jan 2018). Stocks more than 20% below their peak have their score halved, so 14 became 7.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Dishman Carbogen Amcis Ltd: 0.4 × 5 + 0.4 × 21 + 0.2 × 18 = 14, halved to 7 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Dishman Carbogen Amcis Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Lincoln Pharmaceuticals Ltd (Q2 FY27)

    2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it

  • Alivus Life Sciences Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest

  • Strides Pharma Science Ltd (Q2 FY27)

    Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation

  • Laurus Labs Ltd (Q2 FY27)

    2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd